A Phase 4 interventional study of 0.1% brimonidine tartrate ophthalmic solution and 0.01% bimatoprost ophthalmic solution in Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-12-04.
Sponsored by Allergan (part of AbbVie) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing brimonidine in Glaucoma — 1 open to participants now, 1 under way, none of them phase 3. brimonidine · Glaucoma.
Among the 23 studies testing brimonidine in Glaucoma, this one is the 6th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2012, is one of 10 in phase 4, and was the 18th registered.
1,419 studies on the registry are indexed under Glaucoma; 220 are open to participants now.
Browse Glaucoma studies →1 of the 23 studies testing brimonidine in Glaucoma is open now, in 1 country. Recruiting first, the newest first:
Tulane University · Sites in United States
Ages 18+
By country, each count listing its studies:
brimonidine: first FDA approval 1996 (ALPHAGAN), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 154 Glaucoma studies recruiting now, 112 (73%) set no upper age limit and 9 (6%) stop at 75 or younger; 13 take children under 18; 44 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is above the median of 61 across 964 interventional studies indexed under Glaucoma.
Median enrollment 56 across the 21 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
34 studies in Glaucoma by AbbVie: none open now, none under way, none of them phase 3. Of 33 finished, 23 (70%) have results posted.
Among the 34 studies in Glaucoma by AbbVie, this one is the 19th largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2012, is one of 12 in phase 4, and was the 23rd registered.
AbbVie’s Glaucoma studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing brimonidine in Glaucoma, from their registry updates:
Among AbbVie’s 34 in Glaucoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of either bimatoprost 0.01% ophthalmic solution (Lumigan®) alone or bimatoprost 0.01% ophthalmic solution (Lumigan®) and brimonidine tartrate 0.1% ophthalmic solution (Alphagan® P) in combination in patients previously treated with latanoprost 0.005% ophthalmic solution monotherapy who require additional intraocular pressure (IOP) lowering medication.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.1% brimonidine tartrate ophthalmic solution (ALPHAGAN® P) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
Drug: 0.1% brimonidine tartrate ophthalmic solution · Drug: 0.01% bimatoprost ophthalmic solution · Drug: latanoprost 0.005% ophthalmic solution
1 drop of latanoprost 0.005% ophthalmic solution once daily in each eye as run-in therapy for 30 days followed by 1 drop of 0.2% hypromellose lubricant eye drops (used for masking purposes) 3 times per day and 1 drop of 0.01% bimatoprost ophthalmic solution (LUMIGAN®) once per day for 12 weeks.
Drug: 0.01% bimatoprost ophthalmic solution · Drug: 0.2% hypromellose lubricant eye drops · Drug: latanoprost 0.005% ophthalmic solution
1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
Also known as: ALPHAGAN® P
1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
Also known as: LUMIGAN®
1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
Also known as: GenTeal ®
1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP)
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.
Time frame: Baseline, Week 12
| Milestone | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone |
|---|---|---|
| Started | 70 | 67 |
| Completed | 63 | 62 |
| Not completed | 7 | 5 |
IOP is a measurement of the fluid pressure inside the eye. IOP was measured in the study eye, defined as the worse eye at Baseline. The mean diurnal IOP is the average of all the IOP measurements in the study eye taken at 8 AM, 10 AM and 4 PM at Baseline and at Week 12. A negative change from Baseline indicated improvement.
| mm Hg | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone |
|---|---|---|
| Baseline | 22.3 ± 2.22 | 22.2 ± 2.44 |
| Change from Baseline at Week 12 | -4.7 ± 2.55 | -4.0 ± 3.23 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ALPHAGAN® P and LUMIGAN® | — | 1/70 (1.4%) | 4/70 (5.7%) |
| LUMIGAN® Alone | — | 2/67 (3%) | 0/67 (0%) |
| Event | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone |
|---|---|---|
| Prolonged hospitalization cardiac ischemiaCardiac disorders | 0/70 | 1/67 |
| Exacerbation of depression disorderPsychiatric disorders | 0/70 | 1/67 |
| Esophageal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/70 | 0/67 |
| Event | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone |
|---|---|---|
| Ocular hyperemiaEye disorders | 4/70 | 0/67 |
| Age Continuous(Years) | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone | Total |
|---|---|---|---|
| Mean | 65.7 ± 11.87 | 61.1 ± 13.91 | 63.4 ± 13.06 |
| Sex: Female, Male(Participants) | ALPHAGAN® P and LUMIGAN® | LUMIGAN® Alone | Total |
|---|---|---|---|
| Female | 31 | 33 | 64 |
| Male | 39 | 34 | 73 |
The record gives a start of Jan 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Brimonidine · Hypromellose Derivatives